Patient with Brain Tumor Received Extremely Precise Treatment in Reduced Time
SUNNYVALE, California, March 2, 2015 /PRNewswire/ — Accuray Incorporated (Nasdaq: ARAY) announced today that the first patient treatment has been completed using the CyberKnife® M6™ System with the InCise™ Multileaf Collimator (MLC). The treatment was administered as a multidisciplinary effort between Dr. Steven Burton from the Department of Radiation Oncology and Dr. Johnathan Engh from the Department of Neurosurgery at UPMC in Pittsburgh, Pennsylvania. UPMC was one of the InCise MLC evaluation sites working in collaboration with Accuray.
"We have successfully treated the first patient using the CyberKnife M6 System with the InCise MLC. The patient, diagnosed with a brain meningioma, was a typical candidate for highly-focused treatment that can be delivered by the CyberKnife," said Dr. Dwight E. Heron MD, FACRO, FACR, Director of Radiation Services. "With the addition of the MLC, we were able to achieve equivalent precision in tumor targeting and sparing of healthy tissue, but it took us less than half the time — just under 22 minutes — to complete a traditional one hour treatment. The treatment time includes continuous imaging throughout the procedure to ensure accurate dose delivery and the actual time spent delivering the radiation. This real-world case is consistent with our InCise MLC technical evaluation experience and exceeded our expectations in its efficiency."
The M6 Series delivers radiosurgery and stereotactic body radiation therapy, enabling precise, high-quality dose distributions to be confidently administered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients’ quality of life. The system is able to adjust and automatically stay on target in real-time, accounting for patient and tumor motion. CyberKnife is the only robotic radiosurgery system available today which delivers such high precision treatments for intra- and extra-cranial disease sites throughout the body.
"We congratulate Dr. Heron, Dr. Huq and their team on treating the first patient using the CyberKnife M6 System and InCise MLC," said Joshua H. Levine, president and chief executive officer of Accuray. "With the addition of the MLC, clinicians can deliver the same precise radiosurgery treatments they have come to expect with the CyberKnife System, while significantly reducing treatment times, for a wider range of tumor types, including larger and different kinds of tumors than were previously treated."
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to advantages of new technology, clinical applications, clinical results, patient outcomes, successful adoption of Accuray technologies, and Accuray’s leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company’s report on Form 10-K, filed on August 29, 2014, the company’s reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company’s other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.